Tombusviruses, which are small plus-strand RNA viruses of plants, require the viral-coded p33 replication co-factor for template selection and recruitment into replication in infected cells. As presented in the accompanying paper [Shapka, N., Stork, J., Nagy, P.D., 2005. Phosphorylation of the p33 replication protein of Cucumber necrosis tombusvirus adjacent to the RNA binding site affects viral RNA replication. J. Virol. 343, 65 -78.], p33 can be phosphorylated in vitro at serine and threonine residues adjacent to its arginine -proline-rich RNA binding site. To test the effect of phosphorylation on p33 function, in this paper, we used phosphorylation-mimicking aspartic acid mutants of Cucumber necrosis virus (CNV) p33 and in-vitro-phosphorylated p33 in gel mobility shift experiments. We found that phosphorylation inhibited the ability of p33 to bind to the viral RNA. In contrast, the nonphosphorylation-mimicking alanine mutants of p33 bound to viral RNA as efficiently as the nonphosphorylated wild type p33 did. In vitro assays with purified CNV replicase preparations revealed that phosphorylation-mimicking mutants of p33 did not support the assembly of functional CNV replicase complexes in yeast, a model host. Based on these results, we propose that the primary function of reversible phosphorylation of p33 is to regulate the RNA binding capacity of p33, which could affect the assembly of new viral replicase complexes, recruitment of the viral RNA template into replication and/or release of viral RNA from replication. Thus, phosphorylation of p33 might help in switching the role of the viral RNA from replication to other processes, such as viral RNA encapsidation and cell-to-cell movement in infected hosts. D
Introduction
Posttranslational modification of proteins affects the functions and stability of many cellular proteins, such as those involved in the control of gene expression, signal transduction and cell cycle regulation. The most common posttranslational modification is reversible phosphorylation/ dephosphorylation, which could serve as a switch between active and inactive forms of proteins (Hunter and Karin, 1992) . For example, an important cellular antiviral defense system depends on dsRNA-triggered phosphorylation/acti-vation of PKR, which then leads to phosphorylation of eIF2alpha and inhibition of translation (Gunnery and Mathews, 1998) . The Tat protein of Human immunodeficiency virus-1 (HIV) is known to inhibit PKR activity by competing with eIF2 for phosphorylation by the activated PKR. The interaction between Tat and PKR requires the RNA binding region of Tat (Brand et al., 1997; Gunnery and Mathews, 1998) . Phosphorylation of serine/threonine residues is also known to regulate the formation of protein complexes (Pawson and Scott, 1997) , and it can also be used as a signal to trigger ubiquitination and degradation of proteins (King et al., 1996) . Phosphorylation of viral proteins is also common. The examples include regulation of function of the viral movement proteins (MP) in plants (Karpova et al., 1999; Sokolova et al., 1997; Trutnyeva et al., 2005; Waigmann et al., 2000) . The phosphorylated MP binds to the viral RNA less efficiently than the nonphosphorylated form, which might be important in facilitating the release of the bound RNA from the MP:RNA complex during cell-to-cell movement of viral RNAs (Lee and Lucas, 2001; Waigmann et al., 2000) . Binding of coat protein to viral RNA is also inhibited by phosphorylation (Ivanov et al., 2001 (Ivanov et al., , 2003 Kann et al., 1999) . Protein phosphorylation can also regulate intracellular distribution of viral proteins (Kann and Gerlich, 1994) . Another role of phosphorylation/dephosphorylation is to regulate virus replication. For example, protein:RNA interaction and replicase assembly of animal negative-strand RNA viruses are controlled by phosphorylation Gao and Lenard, 1995; Gao et al., 1996; Lenard, 1999; Takacs et al., 1992) . Rapid formation of RNA binding site in the HIV Rev protein is promoted by phosphorylation of serine residues (Fouts et al., 1997) . Similarly, phosphorylation of Rex protein of human T-cell leukemia virus (HTLV) alters the conformation of Rex and its ability to bind to viral RNA, which serves as a switch between the latent and productive phases of the HTLV infection cycle (Narayan et al., 2001; Younis and Green, 2005) . Phosphorylation of replication proteins of animal and plant viruses has also been documented, which could regulate interaction between the replication proteins (Evans et al., 2004; Hericourt et al., 2000; Kim et al., 2002; Puustinen et al., 2002; Street et al., 2004) . However, the role of phosphorylation/dephosphorylation of replication proteins in plusstrand RNA virus replication is currently poorly understood.
Tombusviruses, such as Tomato bushy stunt virus (TBSV) and Cucumber necrosis virus (CNV), are popular model viruses (White and Nagy, 2004) . They have a nonsegmented genomic RNA with five open reading frames (ORF), two of which code for essential replication proteins, termed p33 and p92. The auxiliary p33 is a replication cofactor that plays a role in template selection (Pogany et al., 2005) and recruitment into replication (Monkewich et al., 2005; Panavas et al., 2005) via selectively binding to a conserved stem-loop element [RII-SL(+), a high-affinity binding sequence for p33, termed p33 recognition element, or p33RE; Fig. 1B ] present within the p92 ORF. P33 binds to the viral RNA via its arginine-proline-rich (RPR) domain ( Fig. 1A) , which was shown to be essential for tombusvirus replication Rajendran and Nagy, 2003) , and it also affects subgenomic RNA synthesis and RNA recombination . Together, with the viral RNA, p33 is required for the assembly of the functional replicase complex (Panaviene et al., 2004 , which also contains the p92 RNA-dependent RNA polymerase and possibly host factors. In addition to protein:RNA interactions, the assembly of the replicase might be aided by interactions between p33 and other p33 and p92 molecules, which are essential for replication (Rajendran and Nagy, 2004) . Altogether, p33 seems to be a multifunctional protein affecting viral RNA replication (White and Nagy, 2004) , RNA recombination and possibly other processes (Burgyan et al., 2000) .
Recent identification of phosphorylation-based modification of p33 (see accompanying paper by Shapka et al., 2005) opens up the possibility that the activity of the p33 replication protein might be regulated by phosphorylation/ dephosphorylation in CNV-infected plants. In vitro phosphorylation studies mapped the sites of phosphorylation in p33 to serine (S 210 ) and threonine (T 211 , possibly T 205 ) residues located adjacent to the RNA binding site (Fig. 1C ). Neutral alanine (A) mutations, which mimic the nonphosphorylated form of p33, at these sites were found to affect the synthesis of plus versus minus strands and alter the ratio between the two subgenomic RNAs. On the contrary, the phosphorylation-mimicking aspartic acid (D) mutations that, like phosphorylation, introduced negative charges at these positions rendered the virus non-infectious in plant protoplasts. To determine what functions of p33 (B -C) The positively charged amino acid sequence of the RPR motif involved in RNA binding and the predicted S/T phosphorylation sites are shown. The possible interactions between positively and negatively charged moieties are indicated with dotted lines. The model predicts that the nonphosphorylated p33 could bind stably to the viral RNA, whereas the phosphorylated form might not bind to the viral RNA due to the competition between the negatively charged phosphate groups and the RNA. Note that the hairpin structure illustrates RII(+)-SL with the C I C mismatch, which constitutes p33RE (Pogany et al., 2005) . might be affected by phosphorylation, in the present study, we conducted in vitro RNA binding experiments with recombinant p33 preparations. The obtained data demonstrate that D mutations in p33 at the phosphorylation sites reduced the ability of p33 to bind to viral RNA, while A mutations had lesser effects. We also found that the above D mutations in p33, but not in p92, inhibited the activity and/ or the assembly of functional replicase complexes in yeast. Altogether, we propose that phosphorylation of p33 replication protein is involved in regulation of CNV replication due to affecting the ability of p33 to bind to the viral RNA.
Results

Rationale
Phosphorylation of threonine (T 205 and T 211 ) and serine (S 210 ) residues adjacent to the arginine (R) and proline (P)rich RPR motif (R 213 P 214 R 215 R 216 R 217 P 218 ) ( Fig. 1 ) is predicted to affect the ability of p33 to bind to the viral RNA. This is because phosphorylation makes these residues negatively charged that could ''neutralize'' the proximal positively charged R residues within the RPR motif. Therefore, the negatively charged phosphorylated residues could compete with the negatively charged RNA for binding to the positively charged RPR motif in p33. Overall, we predict that phosphorylation of p33 might affect two functions of p33: facilitating (i) binding/release of the viral RNA to/from the replicase complex during replication; and (ii) assembly/disassembly of the replicase complex, which in addition to p92, also contains the viral RNA, p33 and possible host factors. These models were tested below.
Phosphorylation of p33 adjacent to the RPR motif inhibits viral RNA binding in vitro
To test the effect of phosphorylation on the ability of p33 to bind to the viral RNA, first, we utilized phosphorylation-mimicking mutants of recombinant p33. The phosphorylation-mimicking mutants carried D for T/S mutations, which introduced negative charges comparable to that of phosphorylation (Freye-Minks et al., 2003; Jabbur et al., 2001; Jia et al., 2004; Waigmann et al., 2000) . On the contrary, nonphosphorylated form of p33 was mimicked by A for T/S mutations, which maintain neutral charges at the phosphorylation sites. Moreover, hypo(partial)phosphorylation-mimicking mutants contained a single D mutation at either T 205 , S 210 or T 211 positions. Importantly, both D and A residues are similar in size to T/ S residues, thus minimizing the sterical/structural effects caused by these mutations. However, it is important to note that D mutations only ''mimic'' phosphorylation, thus results obtained with D mutants could possibly cause problems unrelated to phosphorylation.
Altogether, we generated nine p33 mutants with A and/or D mutations at the phosphorylation sites (Figs. 2A -D). These proteins were expressed in E. coli as fusion proteins with the maltose-binding protein (MBP) followed by affinity purification ( Fig. 2E ) as described (Rajendran and Nagy, 2003; Rajendran et al., 2002) . Note that, instead of the fulllength protein, we used a truncated version of p33, which lacked the mostly hydrophobic N-terminal domain. The Nterminal domain contains membrane-anchoring sequences, and it does not contribute to RNA binding in vitro (Pogany et al., 2005; Rajendran and Nagy, 2003) . The purified recombinant p33 was used in a gel electrophoretic mobility-shift assay (EMSA) (Fig. 2) to test its binding to a 32 P-labeled RNA probe consisting of RII(+)-SL, which includes the highaffinity binding sequence p33RE (Pogany et al., 2005) . The EMSA experiments demonstrated that alanine mutations (see A 210 A 211 , Fig. 2A ), which mimic the nonphosphorylated form of p33, had no inhibitory effect on RNA binding by p33. In contrast, the phosphorylation-mimicking D 210 D 211 p33 bound to the RNA probe poorly when compared to the nonphosphorylated p33 control ( Fig. 2B ). Thus, the phosphorylation-mimicking, but not the nonphosphorylationmimicking mutations, inhibited the ability of p33 to bind to the p33RE-containing viral RNA in vitro.
To test which of the three phosphorylation sites (i.e., T 205 , S 210 or T 211 ) have more pronounced effect on RNA binding, we compared additional p33 mutants carrying different combinations of A/D mutations at these phosphorylation sites. The RNA binding abilities of these recombinant p33 proteins revealed that D mutation at position T 211 was especially inhibitory on RNA binding (see mutants D211 and A 210 D 211 , Figs. 2B -C). The presence of D residue at position S 210 also had inhibitory effect on RNA binding (see mutants D 210 and D 210 A 211 , Figs. 2B -C). Phosphorylationmimicking D mutation at position 205 had lesser effect on RNA binding (compare mutant D 205 A 210 A 211 with A 205 A 210 A 211 , Figs. 2D -E). We also tested the RNA binding activity of triple phosphorylation-mimicking mutant (i.e., D 205 D 210 D 211 ), which showed minimal RNA binding activity when compared to the nonphosphorylation-mimicking mutant (A 205 A 210 A 211 ). Altogether, these data suggest that each of the phosphorylation sites (T 205 , S 210 or T 211 ) could be involved in regulation of RNA binding by p33, and their relative effects are inversed with their distances from the RPR motif (see Discussion).
To test if the phosphorylation-mimicking mutation could affect the ability of p33 to bind to plus-and minus-stranded RNA templates, we used EMSA experiments similar to those described above except using full-length model templates representing replication-competent defective interfering RNA (termed DI-72 RNA). While the wt p33C bound efficiently to both DI-72(+) and DI-72(À) RNA, the binding of D 210 D 211 to both RNAs was less efficient (Fig.  3) . Altogether, these data suggest that the overall RNA binding capacity of p33 is inhibited by the presence of phosphorylation-mimicking mutations.
The second approach to test the effect of phosphorylation on the ability of p33 to bind to the viral RNA included in vitro phosphorylation of recombinant wt p33 with protein kinase C (PKC). We used PKC in this experiment because PKC has been found to phosphorylate p33 more efficiently than a plant kinase preparation in vitro (Shapka et al., 2005 accompanying paper) . EMSA performed with the kinased p33 demonstrated that the phosphorylated recombinant p33 bound to the viral RNA probe up to 3-fold less efficiently than the untreated p33 could ( Fig. 4A ). It is likely that PKC treatment had inhibitory effect on RNA binding capacity of p33 due to phosphorylation of S 210 and T 211 because the nonphosphorylatable A 210 A 211 mutant of p33 did not show reduced efficiency of binding in the treated versus untreated samples ( Fig. 4A ). Accordingly, PKC has been shown to phosphorylate only S 210 and T 211 , in p33 in vitro (see the accompanying paper by Shapka et al., 2005) .
Because treatment of p33 with PKC inhibited RNA binding only at low p33 concentrations ( Fig. 4A , Fig. 2 . Reduced RNA binding by the phosphorylation-mimicking p33 mutants in vitro. (A -D) EMSA was performed with various purified recombinant p33 carrying nonphosphorylation-, hypophosphorylation-and phosphorylation-mimicking mutations, respectively, at T 205 , S 210 and/or T 211 positions. The RNA probe was 32 P-labeled RII(+)-SL, which includes p33RE sequence. The proteins were used in increasing amounts (2-fold increase, up to 200 Ag/ml). The migration of the unbound and bound RNAs is shown on the right of the gel images. The experiments were performed three times. (E) Coomassie-stained SDS-PAGE shows that the purified p33 preparations had comparable quantity and quality. lanes 4-5), it is possible that the residual RNA binding by p33 in Fig. 4A (lanes 1 -3) is due to incomplete phosphorylation of all p33 molecules present in solution. To test more rigorously if phosphorylated p33 maintains the ability to bind to the viral RNA probe, we developed a new EMSA assay in which p33 was 32 P-labeled ( Fig. 4B ), whereas the viral RNA [RII(+)-SL probe, Fig. 4B , lanes 4 -5] was unlabeled. Visualization of the viral RNA with ethidium bromide staining and the p33 with Coomassie staining revealed the presence of p33:RNA complexes (Fig. 4B, left and middle panels, lanes 4 -5) that were not present when the mutated DC 99 RNA, which cannot bind to p33 (Pogany et al., 2005) , was used as a probe (Fig. 4B, lanes 2-3) . Importantly, the p33:RNA complexes were not labeled with 32 P (Fig. 4B , right panel, lanes 4 -5), suggesting that the unphosphorylated p33 still present after PKC treatment, but not the phosphorylated p33 ( 32 P-labeled), was responsible for the observed shift in RNA:protein mobility. Based on these experiments, we conclude that the phosphorylated p33 is unlikely to bind to the viral RNA in vitro. Fig. 3 . The nonphosphorylated wt p33 binds both DI-72(+) and (À)RNA more efficiently than the phosphorylation-mimicking mutant. EMSA was performed with purified recombinant p33 preparations, either wt or D 210 D 211 as described under Fig. 2 . The p33 protein was used in increasing amounts (2-fold increase, up to 200 Ag/ml), whereas the same amounts of 32 P-labeled DI-72(+) and DI-72(À) RNAs were applied. The percentage of bound RNA is shown graphically at the bottom. The unbound RNA probe in the absence of p33 is taken as 100%.
Phosphorylation stimulates RNA release from bound p33:RNA complexes in vitro
To test if phosphorylation of p33 could promote the release of the RNA from the p33:RNA complex, we treated the prebound p33:RNA complex with PKC ( Fig. 4C ). This experiment demonstrated that phosphorylation of p33 could promote the release of viral RNA from the complex. The release of RNA from the RNA:p33 complex is due to phosphorylation of S 210 and T 211 because RNA release after PKC treatment was not observed with the nonphosphorylatable A 210 A 211 p33 mutant (Fig. 4C ). In addition, we demonstrated that p33 bound to the viral RNA can be phosphorylated in vitro with PKC ( Fig. 4D) . Therefore, the obtained data are consistent with a model that phosphorylation can stimulate the release of the viral RNA from p33 and/or p33-containing replicase complexes.
Phosphorylation-mimicking p33 mutant inhibits the in vitro activity of functional CNV replicase complex
To test if phosphorylation of p33 affects the activity and/ or the assembly of functional replicases in yeast host, we coexpressed one of the p33 phosphorylation-mimicking mutants with wt p92 and DI-72 RNA as described (Panavas and Nagy, 2003b; Panaviene et al., 2004) . To this end, we prepared two types of replicase preparations 40 h after induction of DI-72 RNA transcription from the pYES-DI-72 expression plasmid. One of the preparations was the membrane-enriched fraction, which contained functional preassembled CNV replicase complexes that could synthesize new RNA strands using the co-purified (endogenous) DI-72 RNA template ( Fig. 5A ) (Panavas and Nagy, 2003b; Panaviene et al., 2004) . The second preparation was obtained by affinity purification of CNV replicase, which is able to use added (exogenous) RNA templates for complementary RNA synthesis ( Fig. 5B) (Panaviene et al., 2004) . In comparison with the control experiments including wt p33 and wt p92, which resulted in highly active CNV replicase preparations, the membrane-enriched and the affinity-purified D 210 D 211 p33-containing CNV replicases were not functional without or with added RNA templates ( Figs. 5A -B ). The amounts of p33 present in these CNV replicase preparations were comparable to those in the wt p33-containing preparations ( Figs. 5A -B) . Thus, the stability and/or expression level of p33 is not affected by the D 210 D 211 mutations in yeast. The simplest explanation of these observations is that the phosphorylation-mimicking D 210 D 211 p33 inhibited the activity and/or the assembly of functional replicase complexes in yeast.
In vitro testing of the CNV replicase activity in preparations containing the nonphosphorylation-mimicking A 210 A 211 and A 205 A 210 A 211 p33 revealed reduced levels of RNA synthesis (between 29 and 45%) in both endogenous and exogenous template-containing reactions ( Figs. 5A -B ). This suggests that the nonphosphorylated p33 could participate in CNV replicase assembly. However, the assembly and/or activity of the CNV replicase containing nonphosphorylation-mimicking p33 is somewhat less efficient than those containing wt p33 (see Discussion). Additional tests revealed that the hypophosphorylationmimicking D 211 p33 supported the activity of CNV replicase by five-fold less efficiently than the wt p33 did (Figs. 5A-B). The amounts of p33 present in these CNV replicase preparations were comparable (Figs. 5A -B) .
To test if similar phosphorylation-mimicking mutation (i.e., D 210 D 211 ) could affect the activity of p92 RdRp protein, we co-expressed the mutated p92 with wt p33 in yeast followed by obtaining CNV replicase preparations. These tests revealed that phosphorylation-mimicking mutation in p92 did not inhibit the activity of the membranebound CNV replicase (Fig. 5A ). This suggests that phosphorylation of p92 at positions S 210 and T 211 is unlikely to affect its polymerase activity in vivo.
CNV replicase containing nonphosphorylation-mimicking p33 shows reduced ratio in plus-versus minus-strand synthesis Reduction of template activity by CNV replicase preparations containing nonphosphorylation-mimicking p33 (Fig. 5 ) suggests that phosphorylation of T 205 , S 210 and Fig. 4 . Phosphorylation inhibits the ability of p33 to bind to the viral RNA and facilitates the release of bound RNA from the p33:RNA complex. (A) EMSA was performed with purified recombinant p33 (wt or A 210 A 211 ) treated prior to RNA binding with PKC in the presence (marked as PKC + ATP) or absence of ATP (marked as ''PKC-ATP''). The probe was the 32 P-labeled RII(+)-SL RNA as described in the legend to Fig. 2 . The percentage of free RNA is shown graphically at the bottom. The free RNA probe in the absence of p33 is taken as 100%. (B) EMSA was performed as described in panel A, except that p33 was phosphorylated with PKC (lanes 2 -5) in the presence of 32 P g-ATP and DC 99 (lanes 1 -3) or wt RII(+)-SL (lanes 4 -5) RNA probes were unlabeled. Lane 1 contains only the DC 99 RNA probe as a marker. Left panel: the gel was stained with ethidium bromide to visualize the RNA probes (DC 99 and wt RII(+)-SL only differ by 1 nt in length). Note the presence of a unique band in lanes 4 -5, which represents the p33:RNA complex (depicted by a double headed arrow). DC 99 RNA probe cannot bind to p33 (Pogany et al., 2005) , thus there is no detectable p33:RNA complex in lanes 2 -3. Middle panel: the same gel as in the left panel was stained with Coomassie blue to visualize p33. Note that the p33:RNA complex (depicted by a double headed arrow) was detected only in lanes 4 -5 at the same position in the gel when compared with the left panel. Right panel: detection of 32 P-labeled p33 with a PhosphorImager from the same gel shown in the left and middle panels. Note the lack of 32 P-labeled p33 (i.e., the phosphorylated form of p33) in the area of p33:RNA complex (depicted by an asterisk). Therefore, these results suggest that the unphosphorylated form of p33, which is apparently still present after PKC treatment, is responsible for the observed RNA mobility shift visualized in the left and middle panels. (C) EMSA was performed with wt 32 P-labeled RII(+)-SL and unlabeled p33 (wt or A 210 A 211 ) as described in panel A, except that the PKC treatment was done after the RNA binding reaction (i.e., after the formation of the stable p33:RNA complex). The percentage of bound RNA is shown below the gel. The free RNA probe in the absence of p33 is taken as 100%. (D) Phosphorylation of purified p33 with PKC using 32 P g-ATP in the presence of RII(+)-SL RNA template (0, 1 or 2 Ag, as shown). Note that PKC can phosphorylate p33 even in the presence of excess amounts of RNA templates.
T 211 sites in wt p33 might play a role in optimal CNV replicase assembly and/or viral RNA synthesis. To test the effect of phosphorylation of p33 on RNA synthesis by the CNV replicase, first, we treated the CNV replicase with PKC prior to the replicase assay. As shown in Figs. 6A-B , PKC treatment had no significant effect on template activity of the CNV replicase bound to its template (endogenous RNA, Fig. 6A ) or on the purified CNV replicase with added template (Fig. 6B) . These data suggest that the preassembled CNV replicase:RNA complex (with the RNA likely bound to the p92 RdRp protein in the replicase complex) is not sensitive to phosphorylation in vitro.
In the second assay, we tested the ratio of in vitro synthesized (+) and (À) strands by the wt and mutated CNV replicases co-purified with their template RNAs (Fig. 7) .
Briefly, in this assay, the ''membrane-enriched'' replicase fraction containing the endogenous viral RNA synthesizes complementary RNA in vitro in the presence of 32 P-UTP and the three other ribonucleotides (''replicase run off'' experiments). The resulting new 32 P-labeled RNA strands are then used as probes in RNA blot experiments that have the same amounts of denatured plus-and minus-strand RNA blotted on the membrane (Panaviene et al., 2004) . Based on measuring hybridization to (+) and (À) strands of viral RNA, we can estimate the ratio of plus-and minus-strand templates present originally in the membrane-enriched fractions. The replicase run off experiments revealed that at the early time point (12 h) the CNV replicase containing nonphosphorylation-mimicking p33 mutant (A 205 A 210 A 211 ) synthesized over 10 times more minus strands than plus strands (Fig. 7) . On the contrary, the wt replicase synthesized almost the same amounts of minus-and plus strands. At 18 h time point, the wt replicase produced¨6 times more plus strands than minus strands, whereas the CNV replicase containing either A 210 A 211 or A 205 A 210 A 211 p33 synthesized only¨3Â and¨1.5Â more plus strands than minus strands. Interestingly, the difference in plus-and minus-strand ratio between the wt and A 205 A 210 A 211 mutant replicase was still¨7-fold at 24 h time point, suggesting that replicase with the nonphosphorylation-mimicking p33 has lower preference for plus-strand synthesis (i.e., less asymmetrical RNA synthesis) than the wt replicase.
The CNV replicase containing hypophosphorylationmimicking p33 (i.e., D 210 A 211 ) lacked detectable level of template activity at the early time points, whereas it Fig. 5 . Phosphorylation-mimicking mutations in p33 inhibit the assembly of functional CNV replicase complexes in yeast. (A) In vitro activity of CNV replicase present in membrane-enriched preparations. Each replicase preparation, obtained from yeast co-expressing p33, p92 and DI-72(+) RNA, was tested with the co-purified endogenous template (no template was added). 32 P-labeled RNA products from the above preparations were analyzed on denaturing 5% PAGE/8 M urea gels. For quantification, we measured the intensity of 32 P-labeled RNA products by using a PhosphorImager. Activity of the CNV replicase obtained from yeast expressing the wt p33 [in addition to wt p92 and DI-72(+) RNA] corresponds to 100%. Each experiment was performed three times.
Western blot (at the bottom) shows the p33 levels in the membrane-enriched preparations. Similar replicase assay with membrane-enriched preparations containing mutated p92 and wt p33 is shown on the right. Note that phosphorylation-mimicking mutations in 92 (D 210 D 211 ), unlike in p33, did not reduce CNV replicase activity. (B) In vitro activity of affinity purified CNV replicase preparations. Each replicase preparation, obtained from yeast co-expressing p33, p92 and DI-72(+) RNA, was tested in the presence of exogenous RI/III(À) template, which contains the minus-stranded regions I and III of DI-72 in a standard CNV replicase assay. Analysis of the replicase products and quantification were done as described in panel A. Western blot (at the bottom) shows the p33 levels in the affinity-purified CNV replicase preparations. produced¨6-fold more plus strands than minus strands at the 30 h time point (Fig. 7) . This suggests that the assembly of CNV replicase is inefficient in yeast expressing D 210 A 211 p33, which could be due to inefficient RNA binding (Fig.  2) , thus inefficient template recruitment into replication.
Discussion
In this work, we characterized the effects of phosphorylation of conserved S/T residues located adjacent to an essential RNA binding domain on the properties of tombus-virus p33 replication protein. Specifically, we found that the phosphorylated form of p33 showed reduced RNA binding in vitro (Figs. 4A -B) . Moreover, phosphorylation of the p33:viral RNA complex with PKC in vitro promoted the release of the viral RNA from the complex (Fig. 4C) . This was further supported by the reduced RNA binding capacity of recombinant phosphorylation-mimicking D for S/T mutants of p33 (Fig. 2) . Altogether, these data are consistent with the model (see Fig. 1 ) that the negative charges introduced at T 205 , S 210 and T 211 adjacent to the RNA binding domain by phosphorylation can inhibit the binding of the negatively charged viral RNA to the positively charged Fig. 7 . Effect of phosphorylation site mutations in p33 on in vitro asymmetrical RNA synthesis by the CNV replicase obtained from yeast. Top: the RNA blots show the (+) and (À) strand synthesis by the in vitro CNV replicase. Unlabeled T7 RNA polymerase transcripts of DI-72(+) and DI-72(À) (400 ng each), marked as + and =, respectively, were blotted on the membrane. The blotted RNAs were then hybridized with denatured 32 P-labeled RNA probes, which were generated by the CNV replicase in vitro on the endogenous templates present in the enriched membrane fractions obtained from yeast. Time points for harvesting the yeast samples for isolation of enriched membrane fractions are shown on the top. Bottom: the ratio between plus-and minus-stranded RNAs in the in vitro replicase assay was calculated based on PhosphorImager analysis from three separate experiments. RPR motif in p33. Based on these characteristics, phosphorylation/dephosphorylation of p33 adjacent to the RNA binding site is likely involved in regulation of p33:viral RNA interaction, and it could serve as an on/off switch in viral RNA binding/RNA release (see below).
In vitro testing of CNV replicase complexes obtained from yeast cells revealed that the purified CNV replicase containing phosphorylation-mimicking p33 (i.e., D 210 D 211 ) lacked replicase activity on an added template (Fig. 5B) . Moreover, the replicase preparation containing D 210 D 211 p33 was also inactive on the co-purified RNA template (Fig.  5A) . The lack of CNV replicase activity could be due to deficiency of phosphorylation-mimicking D 210 D 211 p33 in: (i) binding/holding to the template during the in vitro reaction (Fig. 2) ; and/or (ii) supporting replicase assembly in vivo prior to replicase purification (Fig. 6A) . This is because the viral RNA template is known to stimulate the assembly of functional replicase complexes by 40-to 100fold in tombusviruses (Panaviene et al., 2004 . On the other hand, it is unlikely that translation and/or stability of p33 were altered by these mutations because yeast cells expressed the phosphorylation-mimicking D 210 D 211 p33 in comparable amount to wt p33 (Fig. 4) . On the contrary, the RdRp function of D 210 D 211 p92 was not altered by these modifications, suggesting that phosphorylation of S/T residues adjacent to the RPR motif is expected to have different effect on p92 functions than on p33 functions.
Based on the above and previous observations (Panaviene et al., 2004; Shapka et al., 2005, accompanying paper), we propose that the CNV replicase complex in yeast expressing phosphorylation-mimicking D 210 D 211 p33 lacks template activity likely because it (i) contains reduced amount of viral RNA due to decreased capacity of the mutated p33 in RNA binding, which in turn (ii) leads to deficiency in template recruitment (Pogany et al., 2005) and (iii) inefficient replicase assembly due to limited amount of ''RNA assembly platform'' for p33, p92 and putative host proteins (Panaviene et al., 2004) . Altogether, inefficient replicase assembly in combination with poor template binding and increased RNA release from the replicase complex could explain the lack of detectable CNV replicase activity in membrane-enriched and purified replicase preparations obtained from yeast expressing D 210 D 211 p33 (Figs.  5A -B) . Altogether, we propose that phosphorylation of T 205 , S 210 and T 211 amino acid residues in p33 by a host kinase could lead to ''shut down'' of new replicase assembly and recruitment of viral RNA into replication during the late phase of the replication cycle. This could help in switching the role of the viral RNA from replication to other processes, such as viral RNA encapsidation and possibly cell-to-cell movement in infected hosts. In addition, early hyperphosphorylation of p33 in selected host plants could lead to resistance against tombusviruses by interference with replicase assembly and template binding.
Interestingly, the activity of preassembled replicase complex was not affected by kinase treatment in vitro ( Fig.   6 ), suggesting that phosphorylation of p92 RNA-dependent RNA polymerase within the replicase complex does not alter its ability to bind to the RNA template. This could be due to the presence of two extra RNA binding regions in p92 in addition to the RPR motif (Rajendran and Nagy, 2003) , thus allowing the replicase to perform RNA synthesis on templates that are present within preassembled replication complexes.
The wt nonphosphorylated recombinant p33 and the nonphosphorylation-mimicking A for S/T mutants of p33 bound to viral RNA stably in vitro (Fig. 2) , and they also supported the assembly of functional CNV replicase complexes in yeast (Fig. 5) . These observations are consistent with the model that the nonphosphorylated form of p33 is replication-competent, whereas the fully phosphorylated form is replication incompetent. However, both nonphosphorylated and phosphorylated forms likely play some, albeit different, roles in tombusvirus replication. This is supported by the observation that the CNV replicase containing the phosphorylation incompetent p33 (i.e., A 210 A 211 and A 205 A 210 A 211 ) showed 3-to 7-fold reduction in plus-versus minus-strand synthesis when compared to the CNV replicase containing the wt p33 (Fig. 7) . In other words, the CNV replicase containing the nonphosphorylation-mimicking p33 produced less plus-stranded RNA and/or relatively more minus-stranded RNA than the replicase with the wt p33. This could be due to the reduced release rates of viral RNA templates by the phosphorylation incompetent p33 from the replication sites or altered functionality of the CNV replicase containing A 205 A 210 A 211 p33. Altogether, we propose that phosphorylation plays a role in fine-tuning of the asymmetrical replication process (see below).
The role of phosphorylation of S/T residues adjacent to the RNA binding site in p33 in the replication process could be more complex, however, due to the possible presence of partially (hypo-)phosphorylated p33 forms (see accompanying paper, Shapka et al., 2005) , which might have different functions than the fully phosphorylated form of p33 in infected cells. Accordingly, hypophosphorylation-mimicking p33 mutants (i.e., D 210 A 211 , A 210 D 211 ) showed reduced viral RNA binding in vitro (Fig. 2) when compared to the nonphosphorylated wt p33. In addition, CNV replicase preparations containing D 210 p33 showed reduced template activity and produced small amount of plus-stranded RNA when compared to the replicase preparations with the wt p33 ( Figs. 5A -B) . Overall, hypophosphorylation of p33 could play a role in regulation of subgenomic RNA synthesis (see accompanying paper, Shapka et al., 2005) and fine-tuning of the asymmetrical replication process.
A model on the role of phosphorylation of p33 in regulation of tombusvirus replication
The p33 replication protein plays a role in selection of the viral RNA via selectively binding to a conserved stem-loop region in the p92 ORF [RII(+)-SL representing p33RE] (Monkewich et al., 2005; Panavas et al., 2005; Pogany et al., 2005) . This selective template binding by p33 is important for recruitment of the viral RNA from translation into replication, which takes place in membranous structures derived from peroxisomes (Navarro et al., 2004; . Moreover, the p33:RNA complex is essential for the assembly of the viral replicase complex (Panaviene et al., 2004) , which also contains p92 and possibly host factors. Based on data presented in this and the accompanying paper (Shapka et al., 2005, accompanying paper) , we propose that the template selection and replicase assembly functions are performed by the nonphosphorylated form of p33, and these processes are inhibited by the phosphorylated form of p33. After the assembly of the replicase complex, hypophosphorylation of p33 (probably at S 210 and T 211 positions) could facilitate minus-strand and/or subgenomic RNA synthesis. Phosphorylation of p33 at T 211 position (or combined phosphorylation of T 205 , S 210 and T 211 sites), however, is predicted to decrease the RNA binding capacity of p33 drastically, which could facilitate the release of newly synthesized RNA (both genomic and subgenomic) from the replication units/sites (Fig. 8) . Because phosphorylation and dephosphorylation of p33 might take place repeatedly in cycles, one replication unit could potentially produce and release tombusviral RNA progenies multiple times. Overall, phosphorylation of p33 could help in regulating (fine-tuning) the replication and infection processes.
Cellular processes other than p33 phosphorylation (such as protein modification, protein degradation, diffusion or membrane rearrangements) could also promote the release of viral RNA from the replication units/sites, likely explaining why the nonphosphorylatable p33 (either A 210 A 211 or A 205 A 210 A 211 ) still could support virus replication (Shapka et al., 2005, accompanying paper) . However, the nonphosphorylatable p33 mutants are slower in replication in single cells, and they are less potent in invading the host plants as rapidly as the wt virus can (Shapka et al., 2005, accompanying paper) . Altogether, these deficiencies of the nonphosphorylatable p33 in supporting tombusvirus replication could be especially detrimental in competitive environment where tombusviruses with phosphorylatable p33 are also present.
One of the proposed roles of p33 phosphorylation adjacent to the RNA binding site in fine-tuning the replication process is to regulate/stimulate the release of viral RNA from the replication sites. This might be important because the nonphosphorylated p33 binds the viral RNA rather tightly, which is advantageous for template selection during early steps of replication. On the contrary, at latter steps of replication, tight binding between p33 and the viral RNA could slow down the release of the newly made viral RNAs from the replication sites. This could be disadvantageous because the viral RNA has to participate in other processes, such as translation (i.e., sgRNAs), assembly of new replicase complexes, cell-to-cell movement and encapsidation. Altogether, the current work promotes a novel, fine-tuning role for p33 phosphorylation adjacent to the RNA binding site in tombusvirus replication.
Materials and methods
Expression and purification of recombinant replicase proteins from E. coli Expression and purification of the recombinant CNV p33 replicase protein (termed p33C, lacking the hydrophobic Nterminal domain) were carried out as described earlier Fig. 8 . A model on the role of phosphorylation of p33 in CNV replication. (A) At the beginning of infection, the freshly translated nonphosphorylated p33 is actively involved in the assembly of the CNV replicase, and the recruitment of the viral RNA template to membranous vesicles formed on the surfaces of peroxisomes. The single vesicle schematically shows a hypothetical replication unit, based on BMV (Schwartz et al., 2002) , with numerous p33, several p92 and the (+)-stranded viral RNA (purple). Hypophosphorylation of p33 might affect the ratio of plus-versus minus-strand synthesis by the CNV replicase. (B) Phosphorylation of p33 leads to decreased RNA binding, thus facilitating the release of the newly synthesized genomic and subgenomic RNA progeny from replication. The released viral RNA will likely participate in new rounds of translation, cell-to-cell movement and/or encapsidation. However, at later time point, the phosphorylated p33 cannot participate in the assembly of new CNV replicase complexes, thus resulting in shut down of replication (indicated by an ''X''). A possible role of phosphorylation in the disassembly/degradation of replicase complexes is also shown. (Rajendran and Nagy, 2003; Rajendran et al., 2002) . Briefly, the expression plasmids carrying wt or mutated p33C sequences were transformed into E. coli [Epicurion BL21-CodonPlus (DE3)-RIL (Stratagene)]. Protein expression was induced at 14 -C with 0.3 mM IPTG (isopropylthiogalactopyranoside) for 8 h. The recombinant proteins were purified using amylose resin column (NEB), as described earlier (Rajendran and Nagy, 2003; Rajendran et al., 2002) . All protein purification steps were carried out in a cold room. The purified recombinant proteins were analyzed in a 10% SDS-PAGE for their purity. The Bio-Rad protein assay was used to measure the amount of purified recombinant proteins.
Gel mobility shift assay (EMSA)
RNA templates were obtained using T7 RNA polymerasebased transcription on PCR templates in the presence of 32 P-labeled UTP and unlabeled ATP, CTP and GTP as described (Pogany et al., 2003 (Pogany et al., , 2005 . After phenol/ chloroform extraction and isopropanol/ammonium acetate precipitation, the obtained RNA probes were checked by 5% PAGE/8 M urea electrophoresis.
The affinity purified recombinant proteins (1 Ag or as mentioned in the figure legends) were incubated with 1 ng of radioactively labeled RNA probe (see above) in a binding buffer [50 mM Tris -HCl pH 8.2, 10 mM MgCl 2 , 10 mM DTT, 10% glycerol, 200 ng yeast tRNA (Sigma) and 2 U of RNase inhibitor (Ambion)] at 25 -C for 15 min (Rajendran and Nagy, 2003) . After the binding reaction, the samples were analyzed by 5% non-denaturing polyacrylamide gel electrophoresis in TAE buffer performed at 200V in a cold room (Rajendran and Nagy, 2003) . The gels were dried and analyzed in a PhosphorImager and quantified using ImageQuant v.1.2 (Amersham). To study the effect of phosphorylation on the RNA release from p33, we treated the prebound RNA:p33 complex (see the binding assay above) with PKC (Sigma) as described in the accompanying paper (Shapka et al., 2005) prior to electrophoresis.
Yeast transformation and growth S. cerevisiae strain INVSc1 (Invitrogen) carrying three plasmids [i.e., pGAD-His92, pGBK-His33 and pYC-DI-72(+)Rz, (Panaviene et al., 2004) ] was grown in SC-ULT medium containing 2% galactose for 24 h at 30 -C (Panavas and Nagy, 2003a) . Then, the cultures were diluted 10-fold with fresh SC-ULT medium with 2% galactose and grown at 23 -C until 0.6 -0.7 OD 600 (approximately 24 h). Yeast cells were then harvested by centrifugation at 2000 Â g for 5 min followed by washing the pellet with 20 mM Tris -HCl, pH 8.0 and centrifugation. The pelleted cells were re-suspended in 1 ml of 20 mM Tris -HCl, pH 8.0 buffer, followed by centrifugation at 21,000 Â g for 1 min and storage of the pellet at À80 -C until further use.
CNV replicase assays
First, we obtained ''membrane-enriched'' CNV replicase preparations, which are suitable to test the replicase activity on the endogenous templates present within the CNV replicase preparation (Panaviene et al., 2004) . Frozen yeast cells were homogenized by grinding in liquid nitrogen followed by addition of the extraction buffer (200 mM sorbitol, 50 mM Tris -HCl, pH 7.5, 15 mM MgCl 2 , 10 mM KCl, 10 mM g-mercaptoethanol, yeast protease inhibitor mix, Sigma) and centrifugation at 100 Â g for 1.5 min at 4 -C (Panavas and Nagy, 2003a) . Because no template was added to the in vitro reaction, the replicase preparation could only use the endogenous template present within the enriched membrane fraction. The RdRp products were phenol/chloroform-extracted, precipitated with isopropanol/ammonium acetate and analyzed under denaturing conditions (i.e., 5% PAGE containing 8 M urea (Pogany et al., 2003) .
The second preparation was affinity-purified CNV replicase, which can accept exogenous templates. The CNV replicase was purified via metal-affinity purification as described (Panaviene et al., 2004) . Briefly, the above enriched membrane fraction was solubilized in 1% Triton X-100 and 5% SB3-10 (caprylyl sulfobetaine) (Sigma) followed by binding to ProBond resin (Invitrogen). After careful washing, the recombinant p33 was recovered from the column in the extraction buffer containing 200 mM imidazole and 0.1% Triton X-100. We used 0.5 Ag RNA templates [RI/RIII(À)] and 25 Al of recombinant CNV replicase (Panaviene et al., 2004) . The RdRp products were phenol/chloroform-extracted and analyzed under denaturing conditions (see above).
Plus-and minus-strand assay
To test the ratio of (+) versus (À) strand synthesis on the endogenous templates by the CNV replicase, we obtained the membrane-enriched fraction (see above) followed by standard replicase assay in the presence 32 P-labeled UTP and the other three unlabeled rNTPs followed by phenol/chloroform extraction and isopropanol precipitation. The obtained RNA probe and equal amounts of in vitro transcripts of DI-72(+) and (À) RNAs, prepared by T7 RNA transcription (see above), were denatured separately by heating for 5 min at 85 -C in TE buffer and formamide (in 1:1 ratio). Then, the DI-72(+) and (À)RNAs were separately blotted onto a Hybond XL membrane (Amersham) and crosslinked with UV (GS Gene Linker, Bio-Rad). Hybridization was done using ULTRAhyb solution (Ambion) at 68 -C according to the supplier's instructions. The 32 P-labeled replicase products were used as probes for hybridization.
Western blot
Aliquots (10 Al) of the enriched membrane fraction from yeast cells or the purified p33 preparations in SDS-PAGE sample loading buffer (Sambrook et al., 1989) were heated for 5 min at 85 -C, electrophoresed in 10% SDS-PAGE gels and electrotransferred to a PVDF membrane (Bio-Rad). Then, CNV His-p33 was detected with monoclonal anti-His antibodies (Amersham) and secondary alkaline phosphatase-conjugated anti-mouse antibody (Sigma) as described (Pogany et al., 2005) . Western blots were developed using BCIP and NBT (Sigma).
